Griseofulvin: Difference between revisions
ClaireLewis (talk | contribs) (Created page with "==Administration== *Type: Antifungal *Dosage Forms: *Routes of Administration: Oral *Common Trade Names: ==Adult Dosing== *250-1000mg PO daily ==Pediatric Dosing== *1...") |
Bmurray990 (talk | contribs) |
||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: [[Antifungal]] | *Type: [[Antifungal]] | ||
*Dosage Forms: | *Dosage Forms: Suspension 125mg/5ml; Tablet 125mg, 250mg, 500mg | ||
*Routes of Administration: Oral | *Routes of Administration: Oral | ||
*Common Trade Names: | *Common Trade Names: Grifulvin V, Gris-PEG | ||
==Adult Dosing== | ==Adult Dosing== | ||
Revision as of 20:29, 26 January 2019
Administration
- Type: Antifungal
- Dosage Forms: Suspension 125mg/5ml; Tablet 125mg, 250mg, 500mg
- Routes of Administration: Oral
- Common Trade Names: Grifulvin V, Gris-PEG
Adult Dosing
- 250-1000mg PO daily
Pediatric Dosing
- 13.6-22.7kg: 125-250mg PO daily
- >22.7kg: 250-500mg PO daily
Special Populations
- Pregnancy Rating: B
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing:
- Hepatic dosing:
Contraindications
- Allergy to class/drug
- Hepatocellular failure
- Porphyria
- Pregnancy
Adverse Reactions
Serious
- Acroparesthesia
Common
- Photosensitivity, rash, urticaria
- Nausea/vomiting, diarrhea
- Headache
Pharmacology
- Half-life: 9-22h
- Metabolism: Liver
- Excretion:
Mechanism of Action
- Fungistatic, deposits into keratin precursor cells and inhibits fungal mitosis